查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495981

穿戴式注射器的全球市場：2024-2029 年預測

Global Wearable Injectors Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

穿戴式注射器市場的市場規模預計將從 2022 年的 67.52 億美元增至 2029 年的 251.41 億美元，預測期內複合年成長率為 20.67%。

穿戴式注射器是用於藥物輸送系統的醫療設備。它附著在患者身上並以受控方式輸送藥物。基於同樣的原因，該裝置也稱為貼片幫浦或貼片注射器。這些設備通常用於大量藥物、高黏度藥物以及需要在長時間內定期輸送的藥物。它方便且易於使用，因為它不需要多次痛苦的注射。

穿戴式注射器易於使用，特別是在需要定期給藥時，並且比手動注射具有顯著優勢。全球慢性病流行和生活方式的改變被認為是全球穿戴式注射器市場成長的關鍵驅動力。

穿戴式注射器對使用者友好，可以輕鬆進行自行注射。也不會干擾使用者的日常生活。這些裝置提高了劑量準確性並防止針刺傷。此外，醫療保健成本的上升和技術的變革催生了創新解決方案的出現，這些解決方案可以更有效地進行疾病管理，並減少前往醫院和診所接受注射醫療支援的次數。

市場促進因素：

  • 慢性病的增加和生活方式的改變預計將推動市場成長。

癌症、高血壓、糖尿病和心血管疾病等慢性非傳染性疾病是全世界死亡的主要原因。根據世界衛生組織 (WHO) 的數據，71% 的死亡是由非傳染性疾病 (NCD) 造成的。全球整體每年有 1790 萬人死於心血管疾病。其次是癌症、呼吸道疾病和糖尿病，分別導致 930 萬人、410 萬人和 150 萬人死亡。

穿戴式注射器在心血管疾病、癌症、糖尿病和自體免疫疾病等非傳染性疾病的治療中發揮重要作用。尤其是久坐的生活方式正在興起。這些注射器是經常使用的設備，用於定期注射醫生開出的藥物。這有助於消除藥物過量或劑量不足的可能性。不僅使用方便，還減少了去醫院注射醫療救助的次數，從而節省了時間和金錢。

  • 市場的成長預計將受到技術進步和意識增強的推動。

隨著健康意識的增強、預防措施的提高以及醫療產業研究和開發的增加，穿戴式注射器等解決方案在支持各種非傳染性疾病方面發揮重要作用。隨著人們的健康意識越來越強，他們不僅越來越意識到疾病，而且越來越意識到可用於治療此類疾病的替代療法和醫療設備。

穿戴式輸液幫浦是一種輕巧、緊湊的設備，患者可以將其佩戴在腰帶上，並將插管連接到患者的皮膚上。這些外部注射器非常適合需要長期連續或間歇輸液並允許在治療期間自由活動的患者。大多數胰島素幫浦可以戴在腰帶上，並連接到位於皮下脂肪組織中的輸液器。

各國政府和國際組織已採取多項措施提高公眾意識，以便及時提供援助。此外，技術進步顯著降低了製造成本。透過利用高度發展的自動化，公司可以實現規模經濟。增加利潤和專注於研究和開發更好的解決方案也是優先事項。

市場限制因素：

  • 環境問題可能會阻礙市場成長。

儘管穿戴式注射器是救生設備，但它們卻以環境為補償。這些設備由塑膠製成，僅供一次性使用。設備處理不當或處置不當也很危險。這些設備需要妥善處理，而且並非所有國家都有處理系統，這不僅危害其他人類，而且還損害生態系統，因為塑膠需要很長時間才能分解。

主要進展：

  • 2023 年 5 月 - Viridian Therapeutics, Inc. 與全球醫療保健創新公司 Enable Injections 合作，開始開發和製造穿戴式藥物輸送系統「enFuse(R)」。此合作關係旨在透過在家中或診所進行謹慎的藥物管理來改善患者體驗。隱藏式針頭和免持輸送系統提供了更多的靈活性和便利性。 Enable Injection 專注於改善患者使用藥物傳輸系統的體驗，Viridian Therapeutics 專注於為患有嚴重罕見疾病的患者開發一流的藥物。
  • 2023 年 5 月 - Ipsomed 透過綜合人因服務強化其自動注射器平台，以應對組合藥物開發和監管核准挑戰。該公司向其製藥合作夥伴推出了端到端人因服務，並重建了其設備承包HF 服務。這種全面的服務方法降低了監管核准風險，並加快了我們合作夥伴的上市時間。 Ipsomed 已與 Interface Analysis Associates LLC 建立策略合作夥伴關係，Interface Analysis Associates LLC 是一家領先的 HF服務供應商，擁有支援製藥行業的專業知識。
  • 2023 年 2 月 - Inslet Corporation 收購了 Automated Glucose Control LLC (AGC) 的資產，這是一家總部位於帕洛阿爾託的公司，專門從事自動化胰島素輸送技術的開發和商業化。 Insulet 是無管胰島素幫浦技術的世界領導者，以其 Omnipod(R) 品牌產品而聞名。 Omnipod 胰島素管理系統採用穿戴式設計，可提供長達 3 天不間斷的胰島素輸送，而無需看到或處理針頭。
  • 2022 年 6 月 - BD 和 Frazier Healthcare Partners 同意以 15.25 億美元收購藥局自動化解決方案供應商 Parata Systems。 Parata 的解決方案組合使藥劑師能夠專注於更高價值的臨床業務和患者互動，提高用藥依從性、安全性和患者治療效果。此次收購補充了 BD 在整個護理領域的藥物管理解決方案，包括急診系統、零售藥房、長期照護和家庭環境。此次收購旨在降低成本、提高病患安全並改善病患體驗。此次收購補充了 BD 現有的藥物管理解決方案。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章穿戴式注射器的全球市場：按類型

  • 介紹
  • 體內注射器
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 離體注射器
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章穿戴式注射器的全球市場：依科技分類

  • 介紹
  • 馬達驅動
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 擴充電池
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 彈簧底座
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 旋轉泵
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章穿戴注射器的全球市場：依應用分類

  • 介紹
  • 腫瘤學
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 糖尿病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 循環系統疾病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 自體免疫疾病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球穿戴式注射器市場：依最終用戶分類

  • 介紹
  • 醫院和診所
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 門診手術中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 居家照護中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第9章全球穿戴式注射器市場：按地區

  • 介紹
  • 北美洲
    • 按類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區

第10章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章 公司簡介

  • Medtronic
  • Amgen（Acquired by tenebio）
  • Ypsomed
  • Insulet Corporation
  • West Pharmaceutical Services
  • Becton Dickinson And Company
  • Enable Injections
  • United Therapeutics Corporation
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
簡介目錄
Product Code: KSI061611830

The global wearable injectors market is projected to witness a CAGR of 20.67% during the forecast period to reach a total market size of US$25.141 billion by 2029, increasing from US$6.752 billion in 2022.

Wearable injectors are medical devices used for drug delivery systems. It is attached to the patient to deliver the drugs in a controlled manner. For the same reason, the devices are also called patch pumps or patch injectors. These devices are typically used for high-volume medications, drugs with high viscosities, and medicines that are required at regular intervals over a long period. The device reduces the need for multiple painful injections, making it convenient and user-friendly.

Wearable injectors are easy to use, especially when regular intervals of medication are required, thus providing a significant advantage over manual injections. The growing prevalence of chronic diseases and changing lifestyles around the globe are considered the key drivers for the global wearable injector market growth.

The wearable injectors are user-friendly, making them easy to self-administer. They also do not interfere with the user's day-to-day life. These devices improve dose accuracy and prevent needlestick injuries. Furthermore, rising healthcare costs and changes in technology have come up with innovative solutions that are efficient for managing the disease and also reduce the number of trips to hospitals and clinics to receive medical support for an injection.

Market Drivers:

  • Increasing number of chronic diseases and lifestyle changes is anticipated in the market growth.

Chronic or non-communicable diseases like cancer, hypertension, diabetes, cardiovascular diseases, etc., are the leading causes of death globally. According to the World Health Organisation (WHO), 71% of all deaths are due to non-communicable diseases (NCDs). Globally, 17.9 million people are diseased due to cardiovascular disease annually. This is followed by cancer, respiratory diseases, and diabetes, accounting for 9.3 million, 4.1 million, and 1.5 million deaths, respectively.

Wearable injectors play an important role in managing non-communicable diseases like cardiovascular disease, cancer, diabetes, and autoimmune disease, amongst other diseases. In particular, with the growing sedentary lifestyle. These injectors are highly used devices to deliver drugs prescribed by the doctor at regular intervals. This eliminates the possibility of the drug being over- or under-dosed. Not only is it user-friendly, but it also saves time and money by reducing the number of trips to hospitals for medical assistance for injections.

  • Technological advancement and increasing awareness are anticipated in the market growth.

With the increase in awareness of health, precautionary measures, and increased research and development in the medical industry, solutions like wearable injectors play an important role in assisting with various non-communicable diseases. As individuals are becoming more health-conscious, they are not just becoming aware of diseases but of all the alternative treatments and medical devices that are available for the management of such diseases.

Wearable infusion pumps are lightweight, compact devices that patients wear on their belts with an attached cannula on their skin. These off-body injectors are ideal for patients requiring continuous or intermittent infusions over an extended period, allowing them to move freely during treatment. Most insulin pumps are wearable on the belt, connected to the infusion set in subcutaneous fatty tissue.

Several steps are taken by governments and international organizations to raise awareness amongst the citizens to ensure timely assistance is provided. Further, with technological advancement, the manufacturing cost has been reduced significantly. By using highly advanced automation, companies can reach economies of scale. Increasing profits and focusing more on R&D for better solutions are also priorities.

Market Restraints:

  • Environmental concerns could hamper the market growth.

Though wearable injectors are life-saving devices, they come at a cost to the environment. These devices are made of plastic bodies and are manufactured for one-time use purposes. Mishandling of devices and their improper disposal can also be hazardous. Since these devices need proper disposal and not all countries have a good disposal system, this not only affects other humans but also the ecosystem as plastic takes a long time to decompose.

Key Developments:

  • May 2023 - Viridian Therapeutics partnered with Enable Injections, a global healthcare innovation company, to develop and manufacture the enFuse(R) wearable drug delivery system. The partnership aims to improve patient experience by allowing discreet medication administration at home or in clinics. The hidden needle and hands-free delivery system offer increased flexibility and convenience. Enable Injections focuses on improving the patient experience through drug delivery systems, while Viridian Therapeutics focuses on developing best-in-class medicines for patients with serious and rare diseases.
  • May 2023- Ypsomed is enhancing self-injection device platforms with integrated human factors services to address the challenges of combination drug product development and regulatory approval. The company introduced end-to-end human factors services to its pharmaceutical partners, reshaping device turn-key HF services. This comprehensive service approach de-risks regulatory approval and expedites time-to-market for partners. Ypsomed has entered into a strategic partnership with Interface Analysis Associates LLC, a leading HF service provider with expertise in supporting the pharmaceutical industry. This move reinforces Ypsomed's position as a leading developer and manufacturer of self-injection solutions.
  • February 2023- Insulet Corporation acquired the assets of Automated Glucose Control LLC (AGC), a Palo Alto-based company specializing in developing and commercializing automated insulin delivery technology. Insulet is a global leader in tubeless insulin pump technology, known for its Omnipod(R) brand of products. The Omnipod Insulin Management System offers a wearable design for up to three days of non-stop insulin delivery without the need to see or handle a needle. The Omnipod(R) 5 Automated Insulin Delivery System is a tubeless system integrated with a continuous glucose monitor for blood sugar management.
  • June 2022- BD and Frazier Healthcare Partners agreed to acquire Parata Systems, a pharmacy automation solutions provider, for $1.525 billion. Parata's portfolio of solutions enables pharmacists to focus on higher-value clinical work and patient interactions, improving medication adherence, safety, and patient outcomes. The acquisition complements BD's medication management solutions across the care continuum, including acute care health systems, retail pharmacies, long-term care, and home settings. The deal aims to reduce costs, enhance patient safety, and improve the patient experience. The transaction complement BD's existing medication management solutions.

Segmentation:

By Type

  • On-Body Injectors
  • Off-Body Injectors

By Technology

  • Motor-driven
  • Expanding Battery
  • Spring-based
  • Rotary Pump
  • Others

By Application

  • Oncology
  • Diabetes
  • Cardiovascular Disease
  • Autoimmune Disease
  • Others

By End-User

  • Hospitals and Clinics
  • Ambulatory Surgery Centres
  • Home Care Centres
  • Other

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL WEARABLE INJECTORS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. On-Body Injectors
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Off-Body Injectors
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL WEARABLE INJECTORS MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Motor-driven
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Expanding Battery
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Spring-based
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Rotary Pump
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL WEARABLE INJECTORS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Oncology
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diabetes
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Cardiovascular Disease
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Autoimmune Disease
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness
  • 7.6. Others
    • 7.6.1. Market Opportunities and Trends
    • 7.6.2. Growth Prospects
    • 7.6.3. Geographic Lucrativeness

8. GLOBAL WEARABLE INJECTORS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals and Clinics
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Ambulatory Surgery Centres
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness
  • 8.4. Home Care Centres
    • 8.4.1. Market Opportunities and Trends
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness
  • 8.5. Others
    • 8.5.1. Market Opportunities and Trends
    • 8.5.2. Growth Prospects
    • 8.5.3. Geographic Lucrativeness

9. GLOBAL WEARABLE INJECTORS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Opportunities and Trends
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Opportunities and Trends
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Opportunities and Trends
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Type
    • 9.3.2. By Technology
    • 9.3.3. By Application
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Opportunities and Trends
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Opportunities and Trends
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Opportunities and Trends
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Type
    • 9.4.2. By Technology
    • 9.4.3. By Application
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Opportunities and Trends
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Opportunities and Trends
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. UK
        • 9.4.5.3.1. Market Opportunities and Trends
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Others
        • 9.4.5.4.1. Market Opportunities and Trends
        • 9.4.5.4.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Type
    • 9.5.2. By Technology
    • 9.5.3. By Application
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Opportunities and Trends
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Opportunities and Trends
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Others
        • 9.5.5.3.1. Market Opportunities and Trends
        • 9.5.5.3.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Type
    • 9.6.2. By Technology
    • 9.6.3. By Application
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Opportunities and Trends
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. India
        • 9.6.5.2.1. Market Opportunities and Trends
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. Japan
        • 9.6.5.3.1. Market Opportunities and Trends
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Opportunities and Trends
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Opportunities and Trends
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Opportunities and Trends
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Indonesia
        • 9.6.5.7.1. Market Opportunities and Trends
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Others
        • 9.6.5.8.1. Market Opportunities and Trends
        • 9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Medtronic
  • 11.2. Amgen (Acquired by tenebio)
  • 11.3. Ypsomed
  • 11.4. Insulet Corporation
  • 11.5. West Pharmaceutical Services
  • 11.6. Becton Dickinson And Company
  • 11.7. Enable Injections
  • 11.8. United Therapeutics Corporation
  • 11.9. F. Hoffmann-La Roche AG
  • 11.10. Johnson & Johnson